MedTrace Logo

DAS181 for STOP COVID-19

NCT04354389 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2020-08-11

No results posted yet for this study

Summary

It is a multicenter, randomized, placebo-controlled, double-blind study. The study population is defined as subjects diagnosed with lower respiratory tract COVID-19 who require supplemental oxygen ≥2 LPM at the time of randomization.

Conditions

Interventions

DRUG

DAS181

4.5 mg b.i.d

DRUG

Placebo

q.d. or b.i.d.

DRUG

DAS181

4.5 mg q.d.

Sponsors & Collaborators

  • Ansun Biopharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Jennifer Ho, MD, PhD · Ansun Biopharma, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-25
Primary Completion
2020-09-30
Completion
2020-11-30
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04354389 on ClinicalTrials.gov